Table 4. Pharmacokinetic parameters for pazopanib and lapatinib on day 15 of cycle 1.
|
Dose level |
|
Pazopanib |
Lapatinib |
||||
|---|---|---|---|---|---|---|---|
| Paclitaxel (mg m−2) | Pazopanib (mg) | Lapatinib (mg) | n | AUC(0–24)(μg*hr ml−1) | Cmax(μg ml−1) | AUC(0–24)(μg*hr ml−1) | Cmax(μg ml−1) |
| 50 |
400 |
1000 |
6a |
633 (279, 1436) |
31.7 (14.6, 68.8) |
20.0 (8.90, 44.8) |
1.27 (0.531, 3.02) |
| 50 |
800 |
1000 |
3b |
960 (736, 1620) |
48.9 (40.7, 80.9) |
51.4 (42.3, 71.4) |
3.67 (3.38, 5.46) |
| 80 |
800 |
1000 |
1c |
1027 |
57.4 |
11.6 |
0.95 |
| 80 | 400 | 1000 | 9a | 646 (432, 967) | 32 (21.9, 46.9) | 27.1 (16.7, 43.8) | 1.95 (1.13, 3.37) |
Abbreviations: AUC(0–24)=area under the concentration–time curve from time 0–24 h; Cmax=maximum observed concentration.
a
Data are reported as geometric mean (95% confidence interval).
b
Data are reported as median (range).
c
Individual data values are provided.